Sofosbuvir Velpatasvir Voxilaprevir

Drug Index

Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir.[2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[3] On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.[4] References .mw-parser-output .reflist{fon...

Sofosbuvir + Velpatasvir + Voxilaprevir

Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir.[2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[3] On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.[4] References .mw-parser-output .reflist{fon...

NDC Database

Vosevi Oral Tablet, Film Coated by Gilead Sciences, Inc. ## Markings: GSI;3 ## Shape: Oval ## Color: Gray ## Package Codes: 61958-2401-1 ## Active Ingredients: Sofosbuvir + Velpatasvir + Voxilaprevir